- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears New Features in AI-Powered Mammography Software Suite
Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
A new version of an AI-enabled mammography software may enhance breast cancer detection and bolster workflow efficiency for mammography assessment.
Therapixel’s updated MammoScreen suite has garnered new 510(k) clearances for breast density evaluation and new software that offers a variety of features to help reduce workflow bottlenecks for radiologists.
Therapixel's updated MammoScreen mammography suite garnered a new FDA 510(k) clearance for breast density assessment and clearance of new software, which includes automated pre-reporting that facilitates enhanced efficiency with reporting of mammography findings. (Image courtesy of Therapixel.)
The company said key features include the ability to organize the day’s worklist through a case complexity index; an algorithm that facilitates assessment of 2D and 3D breast imaging and a patient’s prior history; and automated pre-reporting that facilitates enhanced efficiency with reporting of mammography findings.
“With these new features, radiologists can double their reading time savings compared to the previous version. Radiologists will appreciate the reduced fatigue, administrators the improved efficiency and care consistency, and the IT team the seamless one-time installation. We’re proud to launch this new version of MammoScreen, once again delivering unparalleled value to radiologists and patients,” noted Matthieu Leclerc-Chalvet, the chief executive officer of Therapixel.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
